SCHEMBL13319989

SCHEMBL13319989

CCc1ccc(N(S(C)(=O)=O)S(C)(=O)=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.47
HPGD P15428 1/20 0.44
APLNR P35414 1/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 1/20 0.39
EGFR P00533 1/20 0.38
PER2 O15055 1/20 0.38
CRY1 Q16526 1/20 0.38
CRY2 Q49AN0 1/20 0.38
UCHL1 P09936 1/20 0.38
HCRTR2 O43614 1/20 0.38
POLB P06746 1/20 0.38
CYP2C9 P11712 1/20 0.37
TP53 P04637 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
OPRK1 P41145 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5479553 0.81 APLNR (0.39) CA2HPGDAPLNRHTTALDH1A1
SCHEMBL3060002 0.81 APLNR (0.39) CA2HPGDAPLNRHTTALDH1A1
SCHEMBL14668531 0.81 RAB9A (0.48) CA2HPGDHTTALDH1A1EGFR
SCHEMBL2598795 0.79 HRH3 (0.50) CA2APLNRHTTALDH1A1POLB
SCHEMBL5689764 0.78 CA2 (0.48) CA2APLNROPRK1KDM4E
SCHEMBL13886412 0.75 ALDH1A1 (0.38) APLNRALDH1A1PER2CRY1CRY2
SCHEMBL12994623 0.75 MAPT (0.48) CA2HPGDHTTALDH1A1LMNA
SCHEMBL3896543 0.73 LPL (0.52) CA2HPGDHTTALDH1A1CYP2C9
SCHEMBL12304289 0.73 LPL (0.52) CA2HPGDHTTALDH1A1CYP2C9
SCHEMBL1899321 0.73 CA2 (0.40) CA2HTTALDH1A1PER2CRY1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137317-A1 1,2-Disubstituted Heterocyclic Compounds ENVIVO PHARMACEUTICALS, INC. (US) 2010-06-03 US disclosed
US-7294647-B2 Kappa agonist compounds and pharmaceutical formulations thereof ADOLOR CORPORATION (US) 2007-11-13 US disclosed
US-7271270-B2 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2007-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137317-A1 1,2-Disubstituted Heterocyclic Compounds PDE12, PDE7A, PDE10A CA2 2855/4885HPGD 142/4885APLNR 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.